Background:

WQ3810 is an orally active fluoroquinolone, with potent antibacterial activities.

WQ-3810 shows potent activity against A. baumannii, including MDR isolates, with MIC90 of 1 mg/L, more than eight-fold higher than that of ciprofloxacin (64 mg/L) and levofloxacin (8 mg/L). WQ-3810 also exhibits inhibitory effects on E. coli and S. pneumoniae, including FQR isolates, with MIC90 of 4 mg/L and 0.06 mg/L, respectively. WQ-3810 is the most potent among the fluoroquinolones tested against meticillin-resistant Staphylococcus aureus (MRSA) and Neisseria gonorrhoeae, including FQR isolates[1].

[1]. Kazamori D, et al. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens. Int J Antimicrob Agents. 2014 Nov;44(5):443-9.